GSK Arexvy recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices Ruchika Sharma20 April 2025 9:00 AM ISTGSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including...
GSK, Pfizer resolve patent lawsuit over RSV vaccines Ruchika Sharma8 April 2025 5:10 PM ISTPfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing respiratory syncytial virus (RSV)...
GSK RSV vaccine approved in Canada for adults aged 50-59 at increased risk Ruchika Sharma11 Nov 2024 1:00 PM ISTMississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of...
Pfizer wins bid to invalidate 2 GSK patents relating to RSV vaccine Ruchika Sharma9 Oct 2024 2:33 PM ISTLondon: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held by GlaxoSmithKline (GSK)...
USFDA approves expanded age indication for GSK RSV vaccine Arexvy for adults aged 50-59 at increased risk Ruchika Sharma9 Jun 2024 10:00 AM ISTLondon: GSK plc has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine,...
GSK vaccine Arexvy accepted for regulatory review by EMA for adults aged 50-59 at increased risk for RSV Ruchika Sharma4 Feb 2024 10:00 AM ISTLondon: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to expand the use of its...
Pfizer sued by GSK for patent infringement over RSV vaccine Ruchika Sharma3 Aug 2023 12:30 PM ISTA GSK spokesperson said in a statement that intellectual property protections are the "foundation of research-based companies' ability to drive...
GSK RSV shot Arexvy approved in Britain for adults aged 60 years and older Ruchika Sharma10 July 2023 3:30 PM ISTBritain: Britain's health regulator approved GSK's vaccine for the respiratory syncytial virus (RSV), which causes thousands of hospitalisations and...
GSK gets European Commission nod for RSV vaccine Arexvy for older adults Ruchika Sharma7 Jun 2023 1:30 PM ISTRespiratory syncytial virus vaccine, adjuvanted, contains recombinant glycoprotein F stabilised in the prefusion conformation.
FDA approves first-ever vaccine against respiratory syncytial virus for elderly Dr. Kamal Kant Kohli5 May 2023 9:45 AM ISTUSA: The first vaccine against the respiratory syncytial virus has received US FDA's approval and is expected to be available for people aged 60 and...
World's first RSV vaccine: GSK wins USFDA nod for Arexvy in older adults Ruchika Sharma4 May 2023 11:48 AM ISTRespiratory syncytial virus is a common contagious virus affecting the lungs and breathing passages.
